Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Harvey Norman Holdings (HVN.AX)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (A$)	Price Target (A$)	Rating
2022-04-01	5.19	6.50	Buy
2022-06-23	3.71	3.35	Sell
2022-08-31	4.23	3.60	Sell
2022-11-24	4.17	3.85	Sell
2023-02-28	3.85	3.60	Sell
2023-06-20	3.32	3.10	Sell
2023-08-08	3.72	3.25	Sell
2023-09-01	4.12	3.75	Sell
2023-10-28	3.72	3.75	Neutral
2024-01-20	4.30	4.75	Buy
2024-03-01	5.00	5.50	Buy
2024-09-02	4.60	5.00	Buy
2024-11-27	4.90	5.00	Neutral
2025-02-28	5.22	5.25	Neutral

Disclosures

UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.